Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?

Bibliography

• European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908-43
   PubMed Web of Science ®Google Scholar
• IARC. 2012. Available from: http://www-dep.iarc.fr/ [Last accessed 17 September 2014]
   Google Scholar
• Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S303-9
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, Liaw YF, et al. Taiwan Community–Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347(3):168-74
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65-73
   PubMed Web of Science ®Google Scholar
• Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97(4):265-72
   PubMed Web of Science ®Google Scholar
• Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678-86
   PubMed Web of Science ®Google Scholar
• Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis 2013;17:375-97
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu H, Wu S, et al. A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B. Dig Dis Sci 2013;58:815-23
   PubMed Web of Science ®Google Scholar
• Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 2012;35:674-89
   PubMed Web of Science ®Google Scholar
• Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72
   PubMed Web of Science ®Google Scholar
• Liaw YF. Impact of therapy on the long-term outcome of chronic hepatitis B. Clin Liver Dis 2013;17:413-23
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long term lamivudine therapy. Gastroenterology 2003;124:105-17
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJY, Chow WC; on behalf of the CALM study group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-9
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93
   PubMed Web of Science ®Google Scholar
• Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274-6
   PubMed Web of Science ®Google Scholar
• Lampertico P, Soffredini R, Vigano M, et al. Entecavir treatment for Nuc naive, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment [abstract 366]. Hepatology 2012;56:370-1A
   Google Scholar
• Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013;62:760-5
   PubMed Web of Science ®Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow up study. Lancet 2013;381:468-75
   PubMed Web of Science ®Google Scholar
• Manolakopoulos S, Triantos C, Theodoropoulos J, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol 2009;51:468-74
   PubMed Web of Science ®Google Scholar
• Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-61
   PubMed Web of Science ®Google Scholar
• Niro GA, Ippolito AM, Fontana R, et al. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues. J Viral Hepat 2013;20:502-9
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91
   PubMed Web of Science ®Google Scholar
• Lampertico P, Viganó M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-51
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-16
   PubMed Web of Science ®Google Scholar
• Eun JR, Lee HJ, Kim TN, et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53:118-25
   PubMed Web of Science ®Google Scholar
• Kurokawa M, Hiramatsu N, Oze T, et al. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012;47:577-85
   PubMed Web of Science ®Google Scholar
• Kim CH, Um SH, Seo YS, et al. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. J Gastroenterol Hepatol 2012;27:1589-95
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30
   PubMed Web of Science ®Google Scholar
• Chen YC, Jeng WJ, Chien RN, et al. Hepatocellular carcinoma development in HBe-negative hepatitis B cirrhotic patients with entecavir treatment [abstract 521). J Hepatol 2013;58:S214
   Google Scholar
• Lampertico P, Soffredini R, Vigano M, et al. Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment (abstract 366). Hepatology 2012;56:370-71A
   Google Scholar
• Lampertico P, Soffredini R, Viganó M, et al. 5-year entecavir treatment in NUC naive, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics [abstract 755. J Hepatol 2013;58:s306-7
   Google Scholar
• Kim SS, Hwang JC, Lim SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014;109:1223-33
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-47
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-74
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-5
   PubMed Web of Science ®Google Scholar
• Su T, Hu T, Chen C, et al. Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy - A follow-up report of C-TEAM study. Hepatology 2014;60(Suppl 1):abstract LB30
   Google Scholar
• Ahn J, Lim JK, Lee H, et al. Incidence of hepatocellular carcinoma in a national cohort of chronic hepatitis B patients on long term entecavir treatment- the ENUMERATE study [abstract 1870]. Hepatology 2014;60(Suppl 1):1099A
   Google Scholar
• Yasunaka T, Ikeda F, Takaki A, et al. Entecavir reduces the incidence of Vhepatocellular carcinoma in patients with chronic hepatitis B [abstract 1866]. Hepatology 2014;60(Suppl 1):1096A
   Google Scholar
• Buti M, Fung S, Gane E, et al. Clinical, virological, serological and histological outcomes in cirrhotic patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 5 years [abstract 501]. J Hepatol 2012;56:S197-8
   Google Scholar
• Kim WR, Berg T, Loomba R, et al. Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma [abstract 43]. J Hepatol 2013;58:S19
   Google Scholar
• Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77
   PubMed Web of Science ®Google Scholar
• Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011;8:72
   PubMed Web of Science ®Google Scholar
• Singal AK, Salameh H, Kuo YF, et al. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013;38:98-106
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-56
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013;58:427-33
   PubMed Web of Science ®Google Scholar
• Gordon SC, Lamerato LE, Rupp LB, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-93
   PubMed Web of Science ®Google Scholar
• Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014;147:143-51
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Coffin CS, Rezaeeaval M, Pang JX, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther 2014;40:1262-9
   PubMed Web of Science ®Google Scholar
• Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 2014;63:1943-50
   PubMed Web of Science ®Google Scholar
• Lin D, Nguyen NH, Hoang J, et al. Incidence of hepatocellular carcinoma (HCC) in a US cohort of chronic hepatitis B (CHB) patients by Age, Gender, cirrhosis and antiviral treatment status [abstract 232]. Hepatology 2014;60(Suppl 1):315-6A
   Google Scholar
• Papatheodoridis GV, Dalekos GN, Sypsa V, et al. Timing of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in Caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF) [abstract 233]. Hepatology 2014;60(Suppl 1):316A
   Google Scholar
• Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-83
   PubMed Web of Science ®Google Scholar
• Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008;48:88-98
   PubMed Web of Science ®Google Scholar
• Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008;13:875-9
   PubMed Web of Science ®Google Scholar
• Shafritz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981;305:1067-73
   PubMed Web of Science ®Google Scholar
• Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73
   PubMed Web of Science ®Google Scholar
• Ridruejo E, Silva MO. Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Expert Opin Drug Saf 2012;11:357-60
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009;16:265-71
   PubMed Web of Science ®Google Scholar
• Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009;44:470-5
   PubMed Web of Science ®Google Scholar
• Cammá C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602
   PubMed Web of Science ®Google Scholar
• Zhang CH, Xu GL, Jia WD, et al. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer 2011;129:1254-64
   PubMed Web of Science ®Google Scholar
• Jin H, Pan N, Mou Y, et al. Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression. Hepatol Res 2011;41:512-23
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2013;28:31-7
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233-40
   PubMed Web of Science ®Google Scholar
• Hann HW, Coben R, Brown D, et al. A long-term study of the effects of antiviral therapy on survival of patients with HBV associated hepatocellular carcinoma (HCC) following successfully ablated local tumor ablation. Cancer Med 2014;3:390-6
   PubMed Web of Science ®Google Scholar
• Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011;146:675-81
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-13
   PubMed Web of Science ®Google Scholar
• Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013;31:3647-55
   PubMed Web of Science ®Google Scholar
• Yeh YC, Liu CJ, Kuo RN, et al. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One 2014;9:e102051
   Google Scholar